Table 2.
HRs of tendon rupture for each covariate
| Variables | Reference | HR (95% CI) |
| Female | Male | 0.70 (0.69 to 0.72)↡ |
| Black | White | 0.76 (0.73 to 0.78)↡ |
| Hispanic | 0.91 (0.87 to 0.94)↡ | |
| Asian | 0.67 (0.63 to 0.71)↡ | |
| Other | 1.05 (1.01 to 1.09)↑ | |
| Dual ever | Non-Dual Non-LIS | 0.66 (0.64 to 0.68)↡ |
| Non-dual lis | 0.66 (0.63 to 0.70)↡ | |
| Living in rural area | No | 0.94 (0.92 to 0.95)↡ |
| Medicare part d since 2008 | Medicare Part D Since 2007 | 1.03 (1.00 to 1.07) |
| Medicare part d since 2009 | 1.11 (1.07 to 1.15)↟ | |
| Medicare part d since 2010 | 1.16 (1.12 to 1.21)↟ | |
| Medicare part d since 2011 | 1.17 (1.13 to 1.22)↟ | |
| Medicare part d since 2012 | 1.12 (1.08 to 1.16)↟ | |
| Medicare part d since 2013 | 1.03 (1.00 to 1.07) | |
| Medicare part d since 2013 | 1.05 (1.01 to 1.09)↑ | |
| Medicare part d since 2015 | 0.91 (0.87 to 0.96)↡ | |
| Medicare part d since 2016 | 0.93 (0.19 to 4.55) | |
| AMI | No | 0.74 (0.69 to 0.79)↡ |
| Atrial fibrillation | No | 0.94 (0.91 to 0.97)↡ |
| Cataract | No | 1.23 (1.21 to 1.25)↟ |
| Chronic kidney disease | No | 0.92 (0.89 to 0.94)↡ |
| COPD | No | 0.83 (0.81 to 0.86)↡ |
| Heart failure | No | 0.79 (0.77 to 0.82)↡ |
| Diabetes | No | 0.98 (0.96 to 0.99)↓ |
| Glaucoma | No | 1.10 (1.08 to 1.12)↟ |
| Hip/pelvic fracture | No | 0.68 (0.60 to 0.77)↡ |
| Ischaemic heart disease | No | 1.10 (1.08 to 1.12)↟ |
| Depression | No | 1.17 (1.13 to 1.21) |
| Alzheimer’s disease or senile dementia | No | 0.67 (0.63 to 0.71)↡ |
| Osteoporosis | No | 1.03 (1.01 to 1.06)↑ |
| Rheumatoid arthritis/osteoarthritis | No | 2.84 (2.80 to 2.89)↟ |
| Stroke/transient ischaemic attack | No | 0.97 (0.94 to 1.01) |
| Breast cancer | No | 0.94 (0.91 to 0.98)↓ |
| Colorectal cancer | No | 0.79 (0.74 to 0.85)↡ |
| Prostate cancer | No | 1.03 (0.99 to 1.07) |
| Lung cancer | No | 0.39 (0.34 to 0.45)↡ |
| Endometrial cancer | No | 0.85 (0.77 to 0.94)↓ |
| Anaemia | No | 1.01 (0.99 to 1.03) |
| Asthma | No | 1.27 (1.24 to 1.31)↟ |
| Hyperlipidaemia | No | 1.34 (1.31 to 1.36)↟ |
| Hyperplasia | No | 1.13 (1.10 to 1.16)↟ |
| Hypertension | No | 1.09 (1.07 to 1.11)↟ |
| Hypothyroidism | No | 1.08 (1.06 to 1.10)↟ |
| Anxiety disorders | No | 0.98 (0.96 to 1.01) |
| Bipolar disorder | No | 1.02 (0.95 to 1.08) |
| Major depressive affective disorder | No | 1.06 (1.02 to 1.10)↑ |
| Schizophrenia and other psychotic disorders | No | 0.67 (0.61 to 0.74)↡ |
| Epilepsy | No | 0.83 (0.77 to 0.90)↡ |
| Fibromyalgia, chronic pain and fatigue | No | 1.39 (1.36 to 1.42)↟ |
| Viral hepatitis (general) | No | 1.04 (0.96 to 1.13) |
| Liver disease cirrhosis and other liver conditions | No | 0.95 (0.92 to 0.99)↓ |
| Leukaemias and lymphomas | No | 0.94 (0.88 to 1.01) |
| Migraine and other chronic headache | No | 1.28 (1.23 to 1.33)↟ |
| Mobility impairments | No | 0.70 (0.65 to 0.76)↡ |
| Obesity | No | 1.04 (1.02 to 1.06)↑ |
| Peripheral vascular disease | No | 1.00 (0.97 to 1.04) |
| Tobacco use disorders | No | 0.82 (0.80 to 0.85)↡ |
| Pressure ulcers and chronic ulcers | No | 0.82 (0.77 to 0.87)↡ |
| Deafness and hearing impairment | No | 1.21 (1.17 to 1.25)↟ |
HRs and CIs from the primary analysis for covariates except for the study antibiotics (which are in table 3).
↟=very significantly increasedwith P value<0.001, ↑=significantly high with 0.001≤ p<0.05.
↡=very significantly decreased with P value<0.001, ↓=significantly decrease with 0.001≤ p<0.05.
AMC, amoxicillin clavulanate; AMX, amoxicillin; AZT, azithromycin; CIP, ciprofloxacin; FLQ, fluoroquinolone; LEX, cephalexin; LVX, levofloxacin; MXF, moxifloxacin.